Lester Lledo

1.2k total citations
8 papers, 149 citations indexed

About

Lester Lledo is a scholar working on Oncology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Lester Lledo has authored 8 papers receiving a total of 149 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Genetics and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Lester Lledo's work include CAR-T cell therapy research (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (2 papers). Lester Lledo is often cited by papers focused on CAR-T cell therapy research (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (2 papers). Lester Lledo collaborates with scholars based in United States. Lester Lledo's co-authors include Joan Gilmore, Carl H. June, Anne Chew, Michael Kalos, Bruce L. Levine, Alison W. Loren, David L. Porter, Stephan A. Grupp, Simon F. Lacey and Norbert Frey and has published in prestigious journals such as Journal of Clinical Oncology and Blood.

In The Last Decade

Lester Lledo

8 papers receiving 146 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lester Lledo United States	8	126	43	32	29	29	8	149
John Pineda United States	6	174 1.4×	50 1.2×	68 2.1×	46 1.6×	28 1.0×	11	206
Caroline Besley United Kingdom	6	109 0.9×	24 0.6×	20 0.6×	27 0.9×	7 0.2×	16	147
Boyu Hu United States	9	122 1.0×	52 1.2×	25 0.8×	64 2.2×	12 0.4×	34	210
Erin Mullane United States	7	270 2.1×	57 1.3×	70 2.2×	49 1.7×	32 1.1×	15	298
Ana Alarcón Tomás United States	8	177 1.4×	42 1.0×	38 1.2×	50 1.7×	12 0.4×	22	233
Harry Miao United States	9	104 0.8×	16 0.4×	16 0.5×	28 1.0×	10 0.3×	33	149
Sarah Inglott United Kingdom	9	99 0.8×	48 1.1×	35 1.1×	92 3.2×	14 0.5×	15	237
Paolo Strati United States	6	162 1.3×	54 1.3×	53 1.7×	40 1.4×	7 0.2×	21	223
Diana Bouhassira United States	4	84 0.7×	30 0.7×	28 0.9×	30 1.0×	4 0.1×	7	125
Weiliang Song China	7	129 1.0×	40 0.9×	49 1.5×	55 1.9×	5 0.2×	18	183

Countries citing papers authored by Lester Lledo

Since Specialization

Citations

This map shows the geographic impact of Lester Lledo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lester Lledo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lester Lledo more than expected).

Fields of papers citing papers by Lester Lledo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lester Lledo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lester Lledo. The network helps show where Lester Lledo may publish in the future.

Co-authorship network of co-authors of Lester Lledo

This figure shows the co-authorship network connecting the top 25 collaborators of Lester Lledo. A scholar is included among the top collaborators of Lester Lledo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lester Lledo. Lester Lledo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Narayan, Vivek, Julie S. Barber-Rotenberg, Joseph A. Fraietta, et al.. (2021). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 39(6_suppl). 125–125. 14 indexed citations

Narayan, Vivek, Whitney L. Gladney, Gabriela Plesa, et al.. (2020). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). TPS269–TPS269. 20 indexed citations

Uy, Natalie, Edward Pequignot, Noelle V. Frey, et al.. (2020). Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. Blood. 136(Supplement 1). 30–32. 7 indexed citations

Narayan, Vivek, Whitney L. Gladney, Gabriela Plesa, et al.. (2019). A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). TPS347–TPS347. 25 indexed citations

Porter, David L., Norbert Frey, Jan J. Melenhorst, et al.. (2016). Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.. Journal of Clinical Oncology. 34(15_suppl). 3009–3009. 28 indexed citations

Porter, David L., Michael Kalos, Norbert Frey, et al.. (2013). Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL. Blood. 122(21). 4162–4162. 22 indexed citations

Porter, David L., Michael Kalos, Norbert Frey, et al.. (2013). Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL. Blood. 122(21). 873–873. 17 indexed citations

Porter, David L., Stephan A. Grupp, Michael Kalos, et al.. (2012). Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. Blood. 120(21). 717–717. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact